Form 6-K HUTCHMED (China) Ltd For: May 16
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of May 2022
Commission File Number: 001-37710
HUTCHMED (CHINA) LIMITED
(Translation of registrant’s name into English)
48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ⌧ Form 40-F ◻
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ◻
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ◻
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
HUTCHMED (CHINA) LIMITED
Form 6-K
EXHIBIT INDEX
Exhibit No. |
| Description |
| | |
Exhibit 99.1 | | Announcement relating to appointment of non-executive director |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| HUTCHMED (CHINA) LIMITED | |
| | |
| | |
| By: | /s/ Johnny Cheng |
| Name: | Johnny Cheng |
| Title: | Chief Financial Officer |
Date: May 16, 2022
3
Exhibit 99.1
Appointment of Non–Executive Director
Hong Kong, Shanghai & Florham Park, NJ — Monday, May 16, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) announces that Mr Lefei Sun has been appointed as a Non-Executive Director with effect from May 16, 2022 and he will hold office until the next annual general meeting (“AGM”) of HUTCHMED when he will stand for re-election.
The Board of HUTCHMED considers that the appointment of Mr Sun will provide significant benefits to HUTCHMED in view of his experience in capital markets, M&A and business strategy. Aged 42, Mr Sun has been the Managing Director and Head of China Healthcare for General Atlantic since 2018, in charge of private equity investment and portfolio management in the healthcare and life sciences sectors. General Atlantic owns approximately 3% of the ordinary shares of HUTCHMED, through its affiliate General Atlantic Singapore HCM Pte. Ltd.
Mr Simon To, Chairman of HUTCHMED, said, “On behalf of the Board, I would like to extend a warm welcome to Mr Sun. I believe his appointment will further strengthen our Board and we look forward to leveraging the wealth of experience that he brings to the table from his career in life sciences and healthcare investment.”
Before joining General Atlantic, Mr Sun was the Founding Partner of Huatai Healthcare Investment Fund, successfully leading the investment in Mindray Medical, which is listed on Shenzhen Stock Exchange (SZSE:300760). Prior to that, Mr Sun held various investment roles at Credit Suisse and OrbiMed, and a strategy consultant role at McKinsey & Company, all in the healthcare sector. Mr Sun holds a Bachelor of Science degree in Mathematics and Physics from Tsinghua University. He also holds a Master of Arts degree in neuroscience from the Johns Hopkins University.
Mr Sun also has relevant Board experience with both publicly listed and private companies, having held the following directorships in the past five years:
Current Directorships: | Previous Directorships in the last five years: |
Adagene Inc. (Nasdaq:ADAG) | Biotheus Inc. |
Adagene (Hong Kong) Limited | CANbridge Pharmaceuticals Inc. (HKEX:1228) |
Adagene (Suzhou) Ltd | Huatai Healthcare Investment Fund |
Genesis MedTech Group Inc. | Ocumension Therapeutics Inc. (HKEX:1477) |
Hong Kong Asia Medical Holding Limited | |
Under the terms of the appointment of Mr Sun as a non-executive director of the Company until the next AGM, he has agreed that he will not receive any fee for his service and that his appointment will be renewed for successive 12-month periods, unless he is not re-elected at the next AGM or his appointment is otherwise terminated earlier by either party in writing.
Appointment Regulatory Disclosures
Save for the appointments listed above, Mr Sun has held no other directorships during the period of five years prior to his appointment as a director of HUTCHMED. Save for his role with General Atlantic, Mr Sun does not have any relationship with any Directors, senior management or substantial or controlling shareholders of HUTCHMED. Mr Sun does not have any interest in the ordinary shares of HUTCHMED within the meaning of Part XV of the Securities and Futures Ordinance (Cap.571 of the Laws of Hong Kong).
Save for the information disclosed above, there is no other information in relation to Mr Sun that is required to be disclosed pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies or Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and there are no other matters concerning the appointment of Mr Sun that are required to be brought to the attention of the shareholders of HUTCHMED.
About HUTCHMED
HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immuno-therapies for the treatment of cancer and immunological diseases. It has more than 4,600 personnel across all its companies, at the center of which is a team of about 1,700 in oncology/immunology. Since inception it has advanced 12 cancer drug candidates from in-house discovery into clinical studies around the world, with its first three oncology drugs now approved and marketed in China. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.
CONTACTS
Investor Enquiries | |
Mark Lee, Senior Vice President | +852 2121 8200 |
Annie Cheng, Vice President | +1 (973) 567 3786 |
| |
Media Enquiries | |
Americas – Brad Miles, | +1 (917) 570 7340 (Mobile) |
Europe – Ben Atwell / Alex Shaw, | +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) |
+852 9783 6894 (Mobile) | |
| |
Nominated Advisor | |
Atholl Tweedie / Freddy Crossley, | +44 (20) 7886 2500 |
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Arthrex Wins Both Gold and Silver Medals at 2024 Edison Awards
- Engel & Völkers Dallas Fort Worth Presents $20,824 to Special Olympics
- Television Star and Restaurateur Lisa Vanderpump Hosts Grand Opening of Wolf by Vanderpump at Harveys Lake Tahoe
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!